New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:25 EDTAMGN, AMGN, RHHBY, RHHBY, NVS, NVS, MRK, MRK, LBIO, LBIO, INCY, INCY, GSK, GSK, CELG, CELG, BMY, BMY, AZN, AZN, ARRY, ARRY, ZIOP, ZIOPPiper Jaffray biopharm analysts hold an analyst/industry conference call
Analysts, along with a melanoma specialist, discuss the evolving roles of targeted therapies and cancer immunotherapies on an Analyst/Industry conference call. Companies with drugs in development for melanoma include AMGN, ARRY, AZN, BMY, CELG, GSK, INCY, LBIO, MRK, NWLK, NVS, RHHBY and ZIOP and may be discussed on the Analyst/Industry conference call to be held on May 28 at 10 am.
News For AMGN;ARRY;AZN;BMY;CELG;GSK;INCY;LBIO;MRK;NVS;RHHBY;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 15, 2015
11:50 EDTAZNAstraZeneca initiated with a Buy at Societe Generale
09:08 EDTBMYOn The Fly: Pre-market Movers
Subscribe for More Information
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
07:41 EDTAZN, BMYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
07:03 EDTBMYLexicon and Bristol-Myers select development candidate for neuropathic pain
Subscribe for More Information
05:51 EDTZIOPStocks with implied volatility movement; ZIOP MNKD
Subscribe for More Information
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
12:06 EDTAZNFDA panel accepts Onglyza's safety profile in 13-1 vote
Subscribe for More Information
11:36 EDTZIOPZiopharm cancels out of two meetings, Bloomberg reports
Subscribe for More Information
07:31 EDTINCYIncyte to establish European headquarters in Geneva, Switzerland
Subscribe for More Information
07:15 EDTAZNFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
06:30 EDTRHHBYRoche to seek to have cancer drug tested in 11 trials in 2015, Reuters says
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
April 13, 2015
16:51 EDTNVSDiplomat Pharmacy to dispense Novartis' JADENU
Diplomat Pharmacy is set to distribute JADENU, a drug recently approved by the U.S. FDA to treat patients with chronic iron overload. JADENU is a new oral formulation of EXJADE for the treatment of chronic iron overload due to blood transfusions in patients age 2 and older, and chronic iron due to NTDT in patients age 10 and older.
10:01 EDTRHHBYRoche acquires CAPP Medical
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
08:58 EDTAZN, MRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:54 EDTAZNAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
05:21 EDTNVSNovartis to present new data that confirms high efficacy of Gilenya
Novartis announced new Gilenya analyses to be presented at the 67th American Academy of Neurology, or AAN, Annual Meeting in Washington, DC, from April 18-25, showing how Novartis is advancing methods assessing the impact of relapsing multiple sclerosis, or RMS, for patients and physicians. Data will show how adding brain shrinkage to an existing tool to assess MS disease activity will give a more precise prediction of the likelihood of future disability progression. Accurate assessment of disease activity is key to guide treatment decisions in RMS. A pooled analysis from the two-year phase III FREEDOMS and FREEDOMS II trials will further confirm Gilenya's high efficacy in previously-treated patients with highly-active RMS in achieving 'no evidence of disease activity' across four key measures: relapses, MRI lesions, brain shrinkage and disability progression. Achieving NEDA4 is especially critical for highly-active RMS patients, who are likely to lose more physical and cognitive functions over time despite being treated.
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use